Advanced search
Publication Cover
Experimental Lung Research Volume 47, 2021 - Issue 2
Submit an article Journal homepage
2,134
Views
13
CrossRef citations to date
0
Altmetric
Article

BTB and CNC homology 1 inhibition ameliorates fibrosis and inflammation via blocking ERK pathway in pulmonary fibrosis

Yuan Liua Department of Rheumatology, Liuzhou People’s Hospital, Liuzhou, China; View further author information
,
Yongfu Wangb Department of Rheumatology, First Affiliated Hospital of Baotou Medical College, Baotou, China; View further author information
,
Fuai Lub Department of Rheumatology, First Affiliated Hospital of Baotou Medical College, Baotou, China; View further author information
,
Le Wanga Department of Rheumatology, Liuzhou People’s Hospital, Liuzhou, China; View further author information
,
Liu Miaoc Department of Cardiology, Liuzhou People's Hospital, Liuzhou, China; Correspondence[email protected] [email protected]
View further author information
&
Xiaoyuan Wangd Department of Intensive Care Unit, Liuzhou People's Hospital, Liuzhou, ChinaCorrespondence[email protected] [email protected]
View further author information
Pages 67-77 | Received 08 Jul 2020, Accepted 05 Nov 2020, Published online: 26 Nov 2020

References

  • Rosas IO, Dellaripa PF, Lederer DJ, et al. Interstitial lung disease: NHLBI workshop on the primary prevention of chronic lung diseases. Annals ATS. 2014;11(Supplement 3):S169–S177.
  • Hutchinson J, Fogarty A, Hubbard R, et al. Global incidence and mortality of idiopathic pulmonary fibrosis: a systematic review. Eur Respir J. 2015;46(3):795–806. doi:10.1183/09031936.00185114.
  • Hopkins RB, Burke N, Fell C, et al. Epidemiology and survival of idiopathic pulmonary fibrosis from national data in Canada. Eur Respir J. 2016;48(1):187–195. doi:10.1183/13993003.01504-2015.
  • Ley B, Collard HR, King TE, Jr. Clinical course and prediction of survival in idiopathic pulmonary fibrosis. Am J Respir Crit Care Med. 2011;183(4):431–440. doi:10.1164/rccm.201006-0894CI.
  • Raghu G, Chen SY, Yeh WS, et al. Idiopathic pulmonary fibrosis in US Medicare beneficiaries aged 65 years and older: incidence, prevalence, and survival, 2001-11. Lancet Respir Med. 2014;2(7):566–572.
  • Hayes JD, McMahon M, Chowdhry S, et al. Cancer chemoprevention mechanisms mediated through the Keap1-Nrf2 pathway. Antioxid Redox Signal. 2010;13(11):1713–1748. doi:10.1089/ars.2010.3221.
  • Chanda D, Otoupalova E, Smith SR, et al. Developmental pathways in the pathogenesis of lung fibrosis. Mol Aspects Med. 2019;65:56–69. doi:10.1016/j.mam.2018.08.004.
  • Hosseinzadeh A, Javad-Moosavi SA, Reiter RJ, et al. Oxidative/nitrosative stress, autophagy and apoptosis as therapeutic targets of melatonin in idiopathic pulmonary fibrosis. Expert Opin Ther Targets. 2018;22(12):1049–1061. doi:10.1080/14728222.2018.1541318.
  • Ito M, Nagano N, Arai Y, et al. Genetic ablation of Bach1 gene enhances recovery from hyperoxic lung injury in newborn mice via transient upregulation of inflammatory genes. Pediatr Res. 2017;81(6):926–931. doi:10.1038/pr.2017.17.
  • Wiel C, Le Gal K, Ibrahim MX, et al. BACH1 stabilization by antioxidants stimulates lung cancer metastasis. Cell. 2019;178(2):330–345.e22. doi:10.1016/j.cell.2019.06.005.
  • Liu Y, Zheng Y. Bach1 siRNA attenuates bleomycin-induced pulmonary fibrosis by modulating oxidative stress in mice. Int J Mol Med. 2017;39(1):91–100.
  • Edelman BL, Redente EF. Isolation and characterization of mouse fibroblasts. Methods Mol Biol. 2018;1809:59–67. doi:10.1007/978-1-4939-8570-8_5.
  • Martinez FJ, Collard HR, Pardo A, et al. Idiopathic pulmonary fibrosis. Nat Rev Dis Primers. 2017;3:17074. doi:10.1038/nrdp.2017.74.
  • Kreuter M, Swigris J, Pittrow D, et al. The clinical course of idiopathic pulmonary fibrosis and its association to quality of life over time: longitudinal data from the INSIGHTS-IPF registry. Respir Res. 2019;20(1):59.
  • Goven D, Boutten A, Lecon-Malas V, et al. Altered Nrf2/Keap1-Bach1 equilibrium in pulmonary emphysema. Thorax. 2008;63(10):916–924. doi:10.1136/thx.2007.091181.
  • Liu Y, Lu F, Kang L, et al. Pirfenidone attenuates bleomycin-induced pulmonary fibrosis in mice by regulating Nrf2/Bach1 equilibrium. BMC Pulm Med. 2017;17(1):63.
  • Xing J, Wang M, Hong J, et al. TRPM7 channel inhibition exacerbates pulmonary arterial hypertension through MEK/ERK pathway. Aging (Albany NY). 2019;11(12):4050–4065. doi:10.18632/aging.102036.
  • Wang J, Yan G, Guo H, et al. ITE promotes hypoxia-induced transdifferentiation of human pulmonary arterial endothelial cells possibly by activating transforming growth factor-β/Smads and MAPK/ERK pathways. J Cell Biochem. 2019;120(12):19567–19577. doi:10.1002/jcb.29264.
  • Zong D, Li J, Cai S, et al. Notch1 regulates endothelial apoptosis via the ERK pathway in chronic obstructive pulmonary disease. Am J Physiol Cell Physiol. 2018;315(3):C330–C340. doi:10.1152/ajpcell.00182.2017.
  • Cheng CC, Chi PL, Shen MC, et al. Caffeic acid phenethyl ester rescues pulmonary arterial hypertension through the inhibition of AKT/ERK-dependent PDGF/HIF-1alpha in vitro and in vivo. Int J Mol Sci. 2019;20(6):1468.
  • Zhang L, Li Q, Liu Z, et al. The protective effects of bone mesenchymal stem cells on paraquat-induced acute lung injury via the muc5b and ERK/MAPK signaling pathways. Am J Transl Res. 2019;11(6):3707–3721.
  • Nakanome A, Brydun A, Matsumoto M, et al. Bach1 is critical for the transformation of mouse embryonic fibroblasts by Ras(V12) and maintains ERK signaling. Oncogene. 2013;32(27):3231–3245. doi:10.1038/onc.2012.336.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.